In efforts to decrease emergency department (ED) crowding and health care costs, frequent users of ED services have been targeted for interventions to decrease their utilization. Previous studies have had different definitions for frequent users and have considered all frequent users as a...

Cost-effectiveness analysis is versatile and used widely to assist in health care decision making. This chapter discusses how cost-effectiveness analysis is used at the system or national level, particularly in the domain of coverage and payment policy. We describe its relationship to other...

Despite improvements over the past few decades, Slovak health outcomes remains poor compared with most other OECD countries, even after controlling for differences in per capita income and other social, cultural and lifestyle factors. Disparities in access to care and health outcomes between the...

Aktuell weisen die Krankenkassen und der Gesundheitsfonds Überschüsse von über 20 Mrd. Euro auf. Für Daniel Bahr, Bundesminister für Gesundheit, eröffnen diese Überschüsse – neben der Abschaffung der Praxisgebühr – Spielräume für Prämien. Die zentrale Herausforderung an eine...

Aktuell weisen die Krankenkassen und der Gesundheitsfonds Überschüsse von über 20 Mrd. Euro auf. Für Daniel Bahr, Bundesminister für Gesundheit, eröffnen diese Überschüsse – neben der Abschaffung der Praxisgebühr – Spielräume für Prämien. Die zentrale Herausforderung an eine...

This paper analyzes a maximum price system and a reference price system in a vertical differentiation model with a brand-name drug and a generic. In particular, both instruments are compared with respect to their performance in reducing public expenditure, limiting financial exposure of...

As presidential candidates debate health reform, the expression “Medicare for All” (“M4A”) is on repeat, yet few appear to understand precisely what Medicare is or what M4A would mean. Even more striking is that Americans are vigorously debating health reform when the ACA – President...

The United States has state of the art technology and world renowned expertise in medical treatment, yet in terms of healthcare it shows a dramatically poor performance in relation to the other industrialized countries. This situation is surprising, since one would expect that a free market...

This paper presents and evaluates pharmaceutical policies in the EU aimed at the rational use of medicines and at keeping pharmaceutical spending under control. Policy makers are growing more aware that by regulating pharmaceutical markets correctly, considerable savings can be achieved without...